Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224043 | 0.87 | DRD1 (0.58) | DRD1 | |
| SCHEMBL17228660 | 0.87 | DRD1 (0.54) | DRD1MAP4K4 | |
| SCHEMBL17228688 | 0.85 | DRD1 (0.50) | DRD1MAP4K4 | |
| SCHEMBL17228773 | 0.85 | DRD1 (0.50) | DRD1MAP4K4 | |
| SCHEMBL17224055 | 0.84 | DRD1 (0.57) | DRD1 | |
| SCHEMBL17228772 | 0.84 | DRD1 (0.50) | DRD1MAP4K4 | |
| SCHEMBL17228684 | 0.76 | MAP4K4 (0.44) | DRD1MAP4K4 | |
| SCHEMBL17228683 | 0.75 | DRD1 (0.50) | DRD1MAP4K4 | |
| SCHEMBL17224048 | 0.74 | DRD1 (0.52) | DRD1MAP4K4 | |
| SCHEMBL15707627 | 0.74 | DRD1 (0.56) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | claimed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | claimed |
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015166370-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, DRD4 | DRD1 2/4885MAP4K4 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.